Patents by Inventor John Repine

John Repine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957737
    Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: April 16, 2024
    Assignees: COLORADO SEMINARY, OWNER AND OPERATOR OF UNIVERSITY OF DENVER, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: John Repine, Amani Alhalwani
  • Publication number: 20220362349
    Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 17, 2022
    Inventors: John Repine, Amani Alhalwani
  • Patent number: 11376311
    Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 5, 2022
    Assignees: COLORADO SEMINARY, OWNER AND OPERATOR OF UNIVERSITY OF DENVER, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: John Repine, Amani Alhalwani
  • Publication number: 20200261548
    Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 20, 2020
    Inventors: John Repine, Amani Alhalwani
  • Publication number: 20070224287
    Abstract: Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation.
    Type: Application
    Filed: September 27, 2004
    Publication date: September 27, 2007
    Inventors: Richard Wright, John Repine
  • Publication number: 20050256384
    Abstract: Glucose concentration is noninvasively measured by measuring a plurality of absorption values using at least one emitter operating at a corresponding plurality of emission wavelengths through a common optical sample volume and deriving glucose concentration from the absorption measurement values.
    Type: Application
    Filed: May 11, 2004
    Publication date: November 17, 2005
    Applicant: Nostix LLC
    Inventors: Stephen Walker, Peter Nelson, R. Zellers, Charles Henry, John Repine